Leukemia: Oral thalidomide-cyclophosphamide-dexamethasone is an effective and safe regimen for relapsed/refractory adult Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH), a clonal histiocytic tumor, is a rare, heterogeneous histiocytic disorder that occurs in patients of all ages with a variety of clinical manifestations and heterogeneity Prognosis
.

There are no standard therapies available for patients with relapsed/refractory LCH

Langerhans cell histiocytosis (LCH), a clonal histiocytic tumor, is a rare, heterogeneous histiocytic disorder that occurs in patients of all ages with a variety of clinical manifestations and heterogeneity Prognosis

This single-center, single-arm, phase 2 study enrolled 32 patients diagnosed with relapsed/refractory LCH

Figure 1: Response of 32 patients with relapsed/refractory LCH to TCD regimen

Figure 1: Response of 32 patients with relapsed/refractory LCH to TCD regimen

The primary endpoint was event-free survival (EFS)
.

An event was defined as progression or death from any cause during or after TCD treatment

The primary endpoint was event-free survival (EFS)

Figure 2: Survival of R/R Langerhans cell histiocytosis
.

An event-free survival rate valid for the entire cohort

Figure 2: Survival of R/R Langerhans cell histiocytosis

The overall remission rate was 87.

Common toxicities with the TCD regimen included grade 1-2 neutropenia (18.

This study has several limitations

Original source:

Original source:

Wang, Jn.

Wang, Jn.
, Liu, T.
, Zhao, Al.
et al.
Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.
Leukemia (2022).
https://doi.
org/10.
1038 /s41375-022-01555-8.
et al.
Leukemia leave a message here